-
Could rewiring the brain’s “brakes” improve movement in Huntington’s disease?
6 min read
Latest News
-
Revisiting vitamin therapy for HD
6 min read
A small clinical trial of high-dose biotin and thiamine for treating HD is being planned in Spain. This trial is based on research that links HD to another neurodegenerative disease called biotin-thiamine responsive basal ganglia disease (BTBGD).
-
A spoonful of branaplam helps the huntingtin go down
7 min read
Branaplam was originally designed to treat spinal muscular atrophy, but a new paper outlines how it could hold promise for treating Huntington’s. This oral drug lowers huntingtin protein and will now be tested in a study called VIBRANT-HD.
-
Huntington’s disease therapeutics conference 2022 – Day 3
25 min read
Check out research updates from Day 3 of the 2022 HD Therapeutics Conference #HDTC2022
-
Huntington’s disease therapeutics conference 2022 – Day 1
23 min read
Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2022
-
Huntington’s disease therapeutics conference 2022 – Day 2
13 min read
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2022
-
Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
7 min read
A new imaging tool means that scientists can now directly measure the levels of the toxic huntingtin protein in animal models of Huntington’s disease, letting us see how well huntingtin lowering therapies are working in their brains
-
BAC to basics: a more accurate mouse model for Huntington's disease
7 min read
A genetically-tweaked Huntington's disease mouse model shows a tendency for the CAG repeat to grow, just like we see in humans with the mutation.
-
Oral drug may change the story for huntingtin lowering
8 min read
Researchers with PTC Therapeutics recently published exciting new findings – a promising new huntingtin lowering drug that can be taken as a pill. Will this change how we move forward with huntingtin lowering?
-
Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
10 min read
The first round of findings from the halted tominersen huntingtin lowering trial, GENERATION-HD1, run by Roche were shared this week with the HD community. HDBuzz explains what they found and what’s next.
-
KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
7 min read
In a much-needed bit of good news for the Huntington's disease community, Neurocrine Bioscience's KINECT-HD trial showed that treatment with valbenazine significantly reduced the involuntary movements called chorea
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
